ABOG ABOG Oncology & Gynecologic Cancers

Question 1

Which HPV genotypes are most commonly associated with cervical squamous cell carcinoma?

Accepted Answer

HPV 16 and 18

Answer

HPV 16 and 18 account for approximately 70% of cervical squamous cell carcinomas and are classified as high-risk oncogenic types.

Question 2

What is the recommended first-line treatment for early-stage (IA1 without lymphovascular invasion) cervical cancer in a patient desiring fertility preservation?

Accepted Answer

Conization alone

Answer

Stage IA1 cervical cancer without lymphovascular space invasion can be treated with conization (cold knife cone) alone when negative margins are achieved and fertility preservation is desired.

Question 3

Which histologic type of endometrial cancer carries the worst prognosis?

Accepted Answer

Uterine serous carcinoma

Answer

Uterine serous carcinoma (USC) is a Type II endometrial cancer with aggressive behavior, frequent extrauterine spread at diagnosis, and significantly worse prognosis compared to endometrioid subtypes.

Question 4

A patient with ovarian cancer has a BRCA1 germline mutation. Which maintenance therapy is most appropriate after platinum-based chemotherapy?

Accepted Answer

PARP inhibitor (olaparib)

Answer

PARP inhibitors such as olaparib are FDA-approved maintenance therapy for BRCA1/2-mutated ovarian cancer patients who respond to platinum-based chemotherapy, exploiting synthetic lethality.

Question 5

Which tumor marker is most useful for monitoring treatment response in epithelial ovarian cancer?

Accepted Answer

CA-125

Answer

CA-125 is elevated in approximately 80% of epithelial ovarian cancers and is the primary serum marker used to monitor treatment response and detect recurrence.

(ABOG) American Board of Obstetrics & Gynecology Practice Test

(ABOG) American Board of Obstetrics & Gynecology Practice Test

ABOG ABOG Oncology & Gynecologic Cancers